Shots:
- Gilead has reported the P-III (IDEAL) trial data assessing Livdelzi (seladelpar) vs PBO in 96 adults (18-75yrs.) with PBC who have inadequately controlled disease, on or intolerant to ursodeoxycholic acid
- Trial showed that a higher proportion of pts treated with Livdelzi achieved normalization of ALP after 52wks.; data to be presented at a future conference & discussed with global regulatory authorities
- Livdelzi (PO) is a PPAR-delta agonist approved for PBC, which showed anticholestatic, anti-inflammatory, antipruritic, & antifibrotic effects in the preclinical & clinical data to help regulate key metabolic & liver disease pathways
Ref: Businesswire | Image: Gilead | Press Release
Related News: Gilead Reports the US FDA Accelerated Approval of Hepcludex to Treat Chronic Hepatitis Delta Virus (HDV) Infection
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
